{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:54Z","timestamp":1786986894032,"version":"build-2736575974"},"reference-count":81,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.clml.2021.01.012","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T12:05:58Z","timestamp":1611317158000},"page":"368-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in Frontline Management of Peripheral T-cell Lymphoma"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8848-9423","authenticated-orcid":false,"given":"Chathuri","family":"Abeyakoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6655-9876","authenticated-orcid":false,"given":"Carrie","family":"van der Weyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8867-0647","authenticated-orcid":false,"given":"Sean","family":"Harrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9210-5373","authenticated-orcid":false,"given":"Amit","family":"Khot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costas K.","family":"Yannakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.01.012_bib1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib2","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report\u00a0from the prospective, International T-cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.01.012_bib3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2011.08651.x","article-title":"Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)","volume":"153","author":"Dearden","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.01.012_bib4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bjh.13202","article-title":"Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era","volume":"168","author":"Petrich","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.01.012_bib5","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network","volume":"35","author":"Laurent","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2559.2010.03704.x","article-title":"Pathology and biology of peripheral T-cell lymphomas","volume":"58","author":"De Leval","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.clml.2021.01.012_bib7","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.01.012_bib8","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the International Peripheral %-Cell Lymphoma Project","volume":"31","author":"Federico","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib11","first-page":"47","article-title":"The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management","volume":"70","author":"Marchi","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2021.01.012_bib12","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-Cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib13","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib14","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib15","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","article-title":"DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study","volume":"130","author":"Pedersen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib16","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood-2018-03-838524","article-title":"Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"132","author":"Luchtel","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib17","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/bjh.15860","article-title":"Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma","volume":"186","author":"Hapgood","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.01.012_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2011-02-335216","article-title":"Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project","volume":"118","author":"Delabie","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib19","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood.V122.21.3032.3032","article-title":"Hepatosplenic T-cell lymphoma: clinicopathological features and treatment outcomes: report from the North American Peripheral T-Cell Lymphoma Consortium","volume":"122","author":"Shustov","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib20","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/bloodadvances.2018028340","article-title":"Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma","volume":"3","author":"Polprasert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.01.012_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-3-319-99716-2_10","article-title":"Rare T-cell subtypes","volume":"176","author":"van der Weyden","year":"2019","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.clml.2021.01.012_bib22","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.01.012_bib24","first-page":"623924","article-title":"A\u00a0systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma","volume":"2011","author":"AbouYabis","year":"2011","journal-title":"ISRN Hematol"},{"key":"10.1016\/j.clml.2021.01.012_bib25","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience","volume":"103","author":"Escal\u00f3n","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.01.012_bib26","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019etude Des Lymphomes de l\u2019adulte (GELA) Trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-RABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.01.012_bib28","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1080\/10428194.2018.1516873","article-title":"A\u00a0phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma","volume":"60","author":"Hapgood","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.01.012_bib29","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(18)30039-5","article-title":"CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial","volume":"5","author":"Gleeson","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.01.012_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13073-020-00739-0","article-title":"CEOP\/IVE\/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial","volume":"12","author":"Cai","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.clml.2021.01.012_bib31","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib32","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"D\u2019Amore","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib33","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.3390\/cancers12113125","article-title":"role of haematopoietic stem cell transplantation in peripheral T-cell lymphoma","volume":"12","author":"Abeyakoon","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2021.01.012_bib34","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.01.012_bib35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo Study Group","volume":"79","author":"Rodr\u00edguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.01.012_bib36","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib38","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1038\/bcj.2016.63","article-title":"First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation","volume":"6","author":"Wilhelm","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.01.012_bib39","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.01.012_bib40","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","article-title":"Intensified chemo-immunotherapy with\u00a0or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma","volume":"28","author":"Corradini","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.01.012_bib41","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/annonc\/mdu515","article-title":"Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center","volume":"26","author":"Loirat","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib42","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41409-018-0294-2","article-title":"High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI\/Cancer Research UK Phase II study","volume":"54","author":"Phillips","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.01.012_bib44","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2012-11-466839","article-title":"Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT","volume":"121","author":"Jantunen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23992","article-title":"Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort","volume":"90","author":"Nijeboer","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.01.012_bib46","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d\u2019Amore","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib47","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","article-title":"Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK\/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Ma","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.01.012_bib48","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2014.280","article-title":"Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party","volume":"29","author":"Tanase","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.01.012_bib49","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1038\/bcj.2015.43","article-title":"Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma","volume":"5","author":"Rashidi","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.01.012_bib50","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ijrobp.2012.08.015","article-title":"Survival advantage with the addition of radiation therapy to chemotherapy in early stage peripheral T-cell lymphoma, not otherwise specified","volume":"85","author":"Zhang","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2021.01.012_bib51","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2021.01.012_bib52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-134440","article-title":"Final analysis of the Ro-CHOP phase III study (Conducted by LYSA): romidepsin plus CHOP in patients with peripheral T-cell lymphoma","volume":"136","author":"Bachy","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2021.01.012_bib53","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1182\/blood-2018-99-110429","article-title":"Final analysis of the front-line phase III randomized ACT-1 trial in younger patients with systemic peripheral T-cell lymphoma treated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant","volume":"132","author":"d\u2019Amore","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.01.012_bib55","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A\u00a0phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-Cell Consortium Trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.01.012_bib56","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3109\/10428194.2012.742521","article-title":"A\u00a0multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study","volume":"54","author":"Foss","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.01.012_bib57","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2021.01.012_bib58","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2018-99-110354","article-title":"Lenalidomide in combination with CHOP in patients with angioimmunoblastic T-cell lymphoma (AITL): final analysis of clinical and molecular data of a phase 2 Lysa study","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib59","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/annonc\/mdv624","article-title":"A\u00a0phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib60","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clml.2021.01.012_bib61","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2021.01.012_bib62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-134398","article-title":"The Echelon-2 Trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma","volume":"136","author":"Horwitz","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2021.01.012_bib63","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2018-99-112076","article-title":"Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (PTCL) in previously untreated young and elderly patients: pooled analysis of the International ACT-1\/2 phase III trials","volume":"132","author":"Altmann","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib65","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jaad.2018.05.1243","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: clinical features, therapeutic approach, and outcome in a case series of 16 patients","volume":"79","author":"L\u00f3pez-Lerma","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.clml.2021.01.012_bib66","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2340\/00015555-2543","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: immunosuppressive drugs induce better response than polychemotherapy","volume":"97","author":"Michonneau","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clml.2021.01.012_bib67","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","article-title":"Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma","volume":"3","author":"Mehta-Shah","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.01.012_bib68","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/hon.2697","article-title":"Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: a subgroup analysis of the PETAL trial","volume":"38","author":"Schmitz","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib69","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00277-019-03867-9","article-title":"Prognostic significance of FDG-PET\/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomas","volume":"99","author":"Ahn","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.01.012_bib70","doi-asserted-by":"crossref","first-page":"E336","DOI":"10.1097\/RLU.0000000000002516","article-title":"Diagnostic and prognostic value of using 18F-FDG PET\/CT for the evaluation of bone marrow involvement in peripheral T-cell lymphoma","volume":"44","author":"Abe","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.clml.2021.01.012_bib71","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib72","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib73","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-Cell Lymphoma Genotyping on the Liquid Biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib74","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00277-017-3038-2","article-title":"Detection of the circulating tumor DNAs in angioimmunoblastic T-cell lymphoma","volume":"96","author":"Sakata-Yanagimoto","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.01.012_bib75","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib76","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib77","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib78","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood.V110.11.2579.2579","article-title":"First report of a phase II clinical trial of lenalidomide oral therapy for peripheral T-cell lymphoma","volume":"110","author":"Reiman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.01.012_bib79","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A\u00a0phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid\u00ae) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2021.01.012_bib80","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.01.012_bib81","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized phase III study of alisertib or investigator\u2019s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"37","author":"O\u2019Connor","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib82","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2021.01.012_bib83","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.3324\/haematol.2016.146977","article-title":"European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed\/refractory peripheral T-cell lymphoma","volume":"101","author":"Zinzani","year":"2016","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021000203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021000203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:38Z","timestamp":1761870998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021000203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2152265021000203"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.01.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Frontline Management of Peripheral T-cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}